Human Antibody Engineering for Prevention and Treatment of Botulism
A special issue of Toxins (ISSN 2072-6651). This special issue belongs to the section "Bacterial Toxins".
Deadline for manuscript submissions: closed (30 December 2023) | Viewed by 3206
Special Issue Editors
Interests: recombinant antibodies; antibody drugs; antibody engineering
Interests: recombinant antibodies; antibody drug development; antibody manufacturing
Interests: antibody engineering; phage display; yeast display; recombinant antibodies; antibody drugs
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Botulinum neurotoxins have attracted the attention of researchers due to their extreme potency, unique mechanism of action, therapeutic applications, causation of the naturally occurring disease botulism and potential for misuse. While historically polyclonal antitoxins produced from immunized horses or humans have been used to treat botulism, engineered human antibodies produced from cell lines offer a number of significant advantages. The need for engineered human antitoxins has increasing urgency due to renewed concerns about the use of bioweapons and the aging of the existing equine antitoxin stockpile.
The purpose of this Special Issue of Toxins is to report on various antibody engineering efforts on next-generation botulinum antitoxins. The scope of this Special Issue includes the development and application of immunotherapy to treat and prevent botulism from multiple botulinum neurotoxin serotypes.
Dr. Shauna Farr-Jones
Dr. Milan T. Tomic
Prof. Dr. James D. Marks
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a double-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Toxins is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- botulinum antitoxin
- recombinant antibodies
- oligoclonal antibody products
- human antibody drug products
- antibody engineering
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
